The starting line for COVID-19 vaccine development-Reference-Cited by-同舟云学术

The starting line for COVID-19 vaccine development

Published:2020-06 Issue:10240 Volume:395 Page:1815-1816
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lee Nelson,McGeer Allison

Publisher

Elsevier BV

Subject

General Medicine

Reference13 articles.

1. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial;Zhu;Lancet,2020

2. SARS-CoV-2 infection protects against rechallenge in rhesus macaques;Chandrashekar;Science,2020

3. DNA vaccine protection against SARS-CoV-2 in rhesus macaques;Yu;Science,2020

4. Developing COVID-19 vaccines at pandemic speed;Lurie;N Engl J Med,2020

5. The COVID-19 vaccine development landscape;Thanh Le;Nat Rev Drug Discov,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity;Molecular Pharmaceutics;2023-10-19

2. Clinical and immunological characteristics of vaccinated patients with COVID-19;Chinese Medical Journal;2022-07-20

3. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey;Journal of Integrative Medicine;2022-01

4. The race for a COVID-19 vaccine: where are we up to?;Expert Review of Vaccines;2021-12-28

5. Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA;Nanomaterials;2021-10-23